Genetic urogenital tumor

Genetic urogenital tumor (Orphanet code 271844) is a broad classification category within Orphanet that encompasses a group of rare tumors affecting the urogenital system (kidneys, bladder, ureters, urethra, and reproductive organs) that have a defined genetic or hereditary basis. This category includes various inherited cancer predisposition syndromes and genetically driven neoplasms that arise in the genitourinary tract. Examples of conditions that fall under this grouping include hereditary forms of renal cell carcinoma (such as those associated with VHL disease, hereditary papillary renal carcinoma, and Birt-Hogg-Dubé syndrome), Wilms tumor predisposition syndromes, hereditary leiomyomatosis and renal cell cancer, and other genetically determined tumors of the urogenital organs. Clinical features vary widely depending on the specific tumor type and underlying genetic cause, but may include abdominal or flank masses, hematuria (blood in the urine), pain, urinary obstruction, and systemic symptoms such as weight loss or fatigue. Some of these conditions present in childhood (e.g., Wilms tumor), while others manifest in adulthood. Many hereditary urogenital tumor syndromes also have extrarenal manifestations affecting the skin, lungs, or other organ systems. Because this is a classification grouping rather than a single disease entity, treatment approaches depend on the specific diagnosis and may include surgical resection, targeted molecular therapies, immunotherapy, chemotherapy, and active surveillance. Genetic counseling and cascade genetic testing of at-risk family members are important components of management for hereditary forms. Early detection through surveillance protocols tailored to the specific genetic syndrome can significantly improve outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic urogenital tumor